TD Asset Management’s CoLucid Pharmaceuticals, Inc. CLCD Stock Holding History

TD Asset Management’s Portfolio CLCD Stock Details CLCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-55,956	Closed	-$2.04M	–	1457
2016 Q4	$2.04M	Sell	55,956 -400	-0.7%	-$14.2K	﹤0.01%	858
2016 Q3	$2.15M	Buy	56,356 +25,456	+82%	+$376K	﹤0.01%	863
2016 Q2	$252K	Sell	30,900 -500	-2%	-$3.36K	﹤0.01%	1289
2016 Q1	$195K	Sell	31,400 -2,800	-8%	-$17.5K	﹤0.01%	1309
2015 Q4	$286K	Buy	34,200 +1,400	+4%	+$7.37K	﹤0.01%	1246
2015 Q3	$127K	Buy	32,800 +2,400	+8%	+$17.7K	﹤0.01%	1327
2015 Q2	$271K	Buy	+30,400	New	+$261K	﹤0.01%	1284

Other funds holding CLCD

FPF

FNY Partners Fund New York $185M AUM 32.57% 1-Year Est. Return

TD Asset Management's CLCD Position: Q1 2017 in Review

TD Asset Management sold out of CoLucid Pharmaceuticals, Inc. (CLCD) in Q1 2017, closing a stake of 55,956 shares — an estimated $2.04M sold.

TD Asset Management first reported a position in CLCD in Q2 2015 and held it in 7 quarters. The position peaked at $2.15M in Q3 2016. 1 fund tracked by Wall St. Rank holds CLCD as of Q1 2017.

TD Asset Management reported no remaining CoLucid Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
TD Asset Management sold 55,956 CoLucid Pharmaceuticals, Inc. shares in Q1 2017, an estimated $2.04M.
TD Asset Management first reported a position in CoLucid Pharmaceuticals, Inc. in Q2 2015 and held it in 7 quarters.
TD Asset Management's CoLucid Pharmaceuticals, Inc. position peaked at $2.15M in Q3 2016.
1 fund tracked by Wall St. Rank held CoLucid Pharmaceuticals, Inc. as of Q1 2017.

Based on TD Asset Management's 13F filing for Q1 2017, filed 5 May 2017.